Spero Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	171	131	56	78	91	621
Market Cap Growth	392.25%	133.76%	-27.82%	-14.15%	-85.38%	9.38%
Enterprise Value	116	92.12	5.89	5.4	-13.4	528.55
Last Close Price	2.95	2.33	1.03	1.47	1.73	16.01
PE Ratio	11.31	15.53	-	3.42	-	-
Forward PE	4.40	4.88	-	-	-	-
PS Ratio	2.77	1.97	1.17	0.75	1.70	33.99
PB Ratio	3.20	2.23	1.22	0.73	1.20	7.03
P/TBV Ratio	3.19	2.33	1.21	0.73	0.86	5.60
EV/Sales Ratio	1.90	1.38	0.12	0.05	-0.25	28.95
EV/EBITDA Ratio	-	14.59	-	0.25	0.32	-
EV/EBIT Ratio	8.18	14.59	-	0.25	0.32	-
EV/FCF Ratio	16.02	-	-	-	1.73	-
Debt / Equity Ratio	0.01	0.02	0.06	0.04	0.07	0.62
Debt / EBITDA Ratio	0.18	0.46	-	0.25	-	-
Debt / FCF Ratio	0.34	-	-	-	-	-
Net Debt / Equity Ratio	-1.01	-0.63	-1.05	-0.66	-1.35	-1.03
Net Debt / EBITDA Ratio	-3.97	-5.92	0.66	-3.24	2.48	1.04
Net Debt / FCF Ratio	-7.41	2.96	2.07	2.15	13.25	1.41
Asset Turnover	0.96	0.74	0.33	0.68	0.36	0.11
Quick Ratio	10.23	7.40	2.15	4.67	5.09	7.98
Current Ratio	10.50	7.59	2.19	3.53	5.25	8.46
Return on Equity (ROE)	-12.87%	17.30%	-89.62%	30.63%	-56.53%	-81.47%
Return on Assets (ROA)	21.47%	7.24%	-50.09%	15.42%	-28.52%	-54.22%
Return on Invested Capital (ROIC)	125.34%	23.64%	-112.22%	45.44%	-550.73%	-786.58%
Return on Capital Employed (ROCE)	23.78%	10.39%	-70.98%	17.30%	-33.02%	-60.36%
Earnings Yield	8.98%	6.44%	-	29.25%	-	-
Buyback Yield / Dilution	-9.20%	-9.26%	-1.98%	-40.98%	-21.65%	-38.01%
Total Shareholder Return	-9.20%	-9.26%	-1.98%	-40.98%	-21.65%	-38.01%

Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q